Consolidated Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($)	Series A Preferred Stock	Common Stock	Additional Paid-in- Capital	Reserves	Accumulated Other Comprehensive Income/(Loss)	Accumulated Deficit	Total Mawson Stockholders’ Equity	Non- controlling interest	Common Shares	Share Subscription Receivable	Total
Balance at Dec. 31, 2020			$ 34,457,051	$ 652,949	$ (1,341,826)	$ (26,159,539)	$ 7,591,945	$ (27,066)	$ 7,539,275	$ (16,690)	$ 7,564,879
Balance (in Shares) at Dec. 31, 2020
Issuance of common stock, net of offering costs / at-the market offerings		$ 8,592	74,908,585				74,917,177				74,917,177
Issuance of common stock, net of offering costs / at-the market offerings (in Shares)		8,591,948
Issuance of common stock, settlement of convertible note interest s		$ 8,691	750,206				758,897				758,897
Issuance of common stock, settlement of convertible note interest s (in Shares)		86,959
Issuance of common stock, conversion of Series A preferred stock (in Shares)	(178)	17,800
Exchange of stock and Reverse recapitalization of Wize Pharma Inc		$ 461,324	(5,436,541)				(4,975,217)		(7,539,275)		(4,975,217)
Exchange of stock and Reverse recapitalization of Wize Pharma Inc (in Shares)	178	46,132,357
Issuance of common stock, net of offer costs, PIPE transaction		$ 25,000	2,975,000				3,000,000				3,000,000
Issuance of common stock, net of offer costs, PIPE transaction (in Shares)		2,500,000
Issuance of convertible notes, net of offer costs		$ 63,627	20,301,427				20,365,054				20,365,054
Issuance of convertible notes, net of offer costs (in Shares)		6,362,690
Issuance of common stock, exercise of warrants		$ 116		14,781,446			14,781,562		30,613		14,781,562
Issuance of common stock, exercise of warrants (in Shares)		41,000
Fair value of IPR&D acquired, net of Business Combination transaction costs			24,765,831				24,765,831				24,765,831
Issuance of RSU’s and stock options		$ 4,123	1,228,363	10,000,000			11,232,486		(30,613)		11,232,486
Issuance of RSU’s and stock options (in Shares)		212,320
Fair value adjustment of LO2A intellectual property revenue sharing obligation			5,440,863				5,440,863				5,440,863
Late acceptance of Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio		$ 50,558					50,558				50,558
Late acceptance of Exchange of common stock of Cosmos Capital Limited for common stock of Wize Pharma Inc., adjusted to reflect the Exchange Ratio (in Shares)		5,055,813
Issuance of stock by subsidiary to non-controlling interest			163,039				163,039	204,993			368,032
Other		$ (12,272)	(17,129)				(12,711)			16,690	(12,711)
Other (in Shares)		184
Net loss						(47,263,479)	(47,263,479)	(660,191)			(47,923,670)
Other comprehensive income					491,399		491,399				491,399
Non-controlling interest			(917,684)			1,627,938	710,254	534,019			1,244,273
Balance at Sep. 30, 2021		$ 609,759	159,536,695	25,434,395	(850,427)	(73,423,018)	111,307,404	(482,264)			110,825,140
Balance (in Shares) at Sep. 30, 2021		69,001,071
Balance at Jun. 30, 2021		$ 538,899	82,914,768	23,070,525	(6,038,270)	(70,919,532)	29,549,700	(92,868)		(16,690)	29,456,832
Balance (in Shares) at Jun. 30, 2021	178	53,919,268
Issuance of common stock, net of offering costs / at-the market offerings		$ 8,592	74,908,585				74,917,177				74,917,177
Issuance of common stock, net of offering costs / at-the market offerings (in Shares)		8,591,948
Issuance of common stock, on conversion of convertible notes		$ 63,627					63,627				63,627
Issuance of common stock, on conversion of convertible notes (in Shares)		6,362,690
Issuance of common stock, stock based compensation		$ 2,222	817,226				819,448				819,448
Issuance of common stock, stock based compensation (in Shares)		22,222
Issuance of common stock, settlement of convertible note interest s		$ 8,691	750,206				758,897				758,897
Issuance of common stock, settlement of convertible note interest s (in Shares)		86,959
Issuance of common stock, conversion of Series A preferred stock
Issuance of common stock, conversion of Series A preferred stock (in Shares)	(178)	17,800
Issuance of warrants				2,363,870			2,363,870				2,363,870
Issuance of stock by subsidiary to non-controlling interest			163,039				163,039	204,993			368,032
Other		$ (12,272)	(17,129)				(12,711)			16,690	(12,711)
Other (in Shares)		184
Net loss						(2,503,486)	(2,503,486)	(594,389)			(3,097,875)
Other comprehensive income					5,187,843		5,187,843				5,187,843
Balance at Sep. 30, 2021		$ 609,759	159,536,695	25,434,395	(850,427)	(73,423,018)	111,307,404	(482,264)			110,825,140
Balance (in Shares) at Sep. 30, 2021		69,001,071
Balance at Dec. 31, 2021		$ 611,504	165,600,832	20,177,232	(521,094)	(71,123,259)	114,745,215	(164,626)			114,580,589
Balance (in Shares) at Dec. 31, 2021		70,746,508
Issuance of common stock, net of offer costs			5,644,297				5,644,297				5,644,297
Issuance of common stock, net of offer costs (in Shares)		8,023,486
Issuance of common stock, stock based compensation		$ 19	134,879	408,585			543,483				543,483
Issuance of common stock, stock based compensation (in Shares)		18,787
Issuance of warrants			(10,243,200)	11,411,033			1,167,833				1,167,833
Issuance of RSU’s and stock options		$ 2,454	6,037,506	(5,680,292)			359,668				359,668
Issuance of RSU’s and stock options (in Shares)		2,460,987
Net loss						(34,315,041)	(34,315,041)	(912,449)			(35,227,490)
Other comprehensive income					4,418,476		4,418,476	34,380			4,452,856
Balance at Sep. 30, 2022		$ 613,977	166,256,630	26,316,558	3,897,382	(103,810,362)	93,274,185	(508,676)			92,765,509
Balance (in Shares) at Sep. 30, 2022		81,249,768
Balance at Jun. 30, 2022		$ 613,250	169,026,637	17,104,426	(2,530,052)	(82,952,860)	101,261,401	(140,227)			101,121,174
Balance (in Shares) at Jun. 30, 2022		72,491,295
Issuance of common stock, net of offer costs			5,644,298				5,644,298				5,644,298
Issuance of common stock, net of offer costs (in Shares)		8,023,486
Issuance of warrants			(10,243,200)	10,743,700			500,500				500,500
Issuance and exercising of RSU’s and stock options		$ 727	1,828,895	(1,531,568)			298,054				298,054
Issuance and exercising of RSU’s and stock options (in Shares)		734,987
Net loss						(20,861,982)	(20,861,982)	(389,801)			(21,251,783)
Other comprehensive income					6,427,434	4,480	6,431,914	21,352			6,453,266
Balance at Sep. 30, 2022		$ 613,977	$ 166,256,630	$ 26,316,558	$ 3,897,382	$ (103,810,362)	$ 93,274,185	$ (508,676)			$ 92,765,509
Balance (in Shares) at Sep. 30, 2022		81,249,768